Abstract Number: 2165 • ACR Convergence 2025
Targeted Needs Assessment of Provider Medical Knowledge of Juvenile Scleroderma, a Mixed Methods Study
Background/Purpose: Juvenile scleroderma (JS) is an autoimmune disease that can cause skin sclerosis leading to deformity, disability, and early mortality especially with delayed diagnosis. A…Abstract Number: 1582 • ACR Convergence 2025
Risk factors for incident digital ischemic complications in systemic sclerosis in the Collaborative National Quality and Efficacy Registry (CONQUER)
Background/Purpose: There have not been large US-based studies of digital pitting scars (DPS) and digital ischemic ulcers (DIU) in systemic sclerosis. Utilizing the Collaborative National…Abstract Number: 0965 • ACR Convergence 2025
Inhibition of Nicotinamide N-Methyltransferase Reverses Fibroblast Activation via Epigenetic and Metabolic Remodeling in Systemic Sclerosis
Background/Purpose: Systemic sclerosis (SSc) is characterized by progressive fibrosis driven by sustained fibroblast activation and senescence. Nicotinamide N-methyltransferase (NNMT), a SAM-dependent enzyme, is upregulated in…Abstract Number: 0681 • ACR Convergence 2025
Evaluation of Serial Cardiovascular Magnetic Resonance Monitoring and Immunosuppressive Therapy in Predicting Long-Term Outcomes in Systemic Sclerosis
Background/Purpose: Systemic sclerosis (SSc) is a connective tissue disease that can manifest as widespread skin and visceral fibrosis, potentially affecting major organs including the heart.…Abstract Number: 2047 • ACR Convergence 2025
Trends in Lung Transplant Listing Outcomes in Connective Tissue Disease associated Interstitial Lung Disease (CTD-ILD) Across Two Decades
Background/Purpose: Lung transplantation represents a potential life-extending therapy for patients with advanced CTD-ILD. This study aims to characterize lung transplant listing outcomes among CTD-ILD patients…Abstract Number: 1583 • ACR Convergence 2025
Epidemiology, Outcome and Expenditures of Hospitalized Patients with Systemic Sclerosis: National Inpatient Sample 2021
Background/Purpose: The inpatient epidemiology, morbidity, mortality, and healthcare expenditures of patients with systemic sclerosis (SSc) are not well-characterized. This study aims to utilize a nationwide…Abstract Number: 0966 • ACR Convergence 2025
Integrated Bulk and Single Cell Analysis Confirms Differential Upregulation of the Proton Sensing Receptor GPR68 in Systemic Sclerosis Across Disease Stage and Subset
Background/Purpose: The cell surface protein GPR68 (ovarian cancer G protein-coupled receptor 1, OGR1) is a proton-sensing G-protein-coupled receptor (GPCR) that responds to extracellular acidity and…Abstract Number: 0677 • ACR Convergence 2025
Increased incidence of sudden cardiac death in systemic sclerosis: estimate & correlates.
Background/Purpose: The incidence of sudden cardiac death (SCD) is suspected to be increased in systemic sclerosis (SSc). However, data describing SCD incidence in SSc are…Abstract Number: 1969 • ACR Convergence 2025
Enhancing Objective Evaluation of Raynaud’s in Veterans with Scleroderma-related Hand Pain: Integrating Patient Reported Outcomes and Nailfold Capillaroscopy
Background/Purpose: Raynaud’s phenomenon (RP) is a painful and disabling feature of systemic sclerosis (SSc) that significantly impairs quality of life. Tools that integrate subjective symptom…Abstract Number: 1574 • ACR Convergence 2025
A rise in serum KL-6 levels predicts subsequent progressive pulmonary fibrosis in patients with systemic sclerosis-associated interstitial lung disease
Background/Purpose: Interstitial lung disease (ILD) is leading cause of morbidity and mortality in patients with systemic sclerosis (SSc). Given the high variable clinical course of…Abstract Number: 0959 • ACR Convergence 2025
Longitudinal Multiomic Study of Skin, Peripheral Blood, and Serum: Serum Proteome Reflects the Disease Process at the End-organ Level and Predicts the Course of Modified Rodnan Skin Score
Background/Purpose: Clinically useful biomarkers for systemic sclerosis (SSc) are needed. While obtaining samples from affected organs like the skin and lungs is invasive and cannot…Abstract Number: 0884 • ACR Convergence 2025
Risk Score for Early Mortality to stratify for Intensive SSc Therapy
Background/Purpose: Systemic sclerosis (SSc) is a rare disease that often leads to severe complications and premature mortality. Recent advancements in the field have led to…Abstract Number: 1966 • ACR Convergence 2025
Assessing the Impact of Cutaneous Melanin on Microvascular Oxygenation Measurement in Systemic Sclerosis Using Multispectral Imaging
Background/Purpose: Microvascular abnormalities, leading to hypoxia, drive the SSc disease process. Accurate measurement of skin oxygenation, both baseline and during ‘stress’/reperfusion (which can be mimicked…Abstract Number: 1570 • ACR Convergence 2025
Hydroxychloroquine and Disease Progression in Systemic Sclerosis: Insights from Antibody-Stratified Survival Analyses
Background/Purpose: Hydroxychloroquine (HCQ) is an antimalarial drug that interferes with dendritic cells and monocytes, acidifies endosomes, and modulates toll-like receptors, reducing autoimmune responses and cell…Abstract Number: 0958 • ACR Convergence 2025
Asynchronous Resolution of Inflammation and Fibrosis in A Prolonged Experimental Model Suggests Distinct Temporal Dynamics And Resolution Mechanisms in Systemic Sclerosis
Background/Purpose: Systemic sclerosis (SSc) is characterized by tissue fibrosis, which is defined as excessive and irreversible extracellular matrix (ECM) accumulation, leading to organ dysfunction. In…
- « Previous Page
- 1
- 2
- 3
- 4
- 5
- …
- 33
- Next Page »
